- RecruitingPhase I/II
A 2-part, randomized, double-blind, placebo-controlled study in participants with Duchenne muscular dystrophy amenable to exon 44 skipping to evaluate the safety and efficacy of ENTR-601-44 (ELEVATE-44)
This study looks at a new medicine, ENTR-601-44, for Duchenne muscular dystrophy (DMD) in boys and young men aged 4-20. We want to see if it's safe, what side effects it has, and if it helps muscles work better by increasing a protein called dystrophin.
For: Duchenne muscular dystrophy (DMD)United Kingdom · Belgium · Italy - RecruitingPHASE1, PHASE2
A Study in Participants With Duchenne Muscular Dystrophy Amenable to Exon 44 Skipping to Evaluate the Safety and Efficacy of ENTR-601-44
This study looks at a new medicine, ENTR-601-44, for Duchenne muscular dystrophy (DMD). We want to see if it's safe, what side effects it might have, and if it helps people with DMD. It involves regular check-ups and is for males aged 4-20.
For: Duchenne Muscular Dystrophy (DMD)Belgium · Italy · Spain - Not yet recruitingPHASE2
Long-Term Extension Study in Participants With Duchenne Muscular Dystrophy Amenable to Exon Skipping to Evaluate the Safety and Efficacy of Endosomal Escape Vehicle Phosphorodiamidate Morpholino Oligomer Platform Products (ELEVATE-LTE)
This study looks at new trial medicines, ENTR-601-44 and ENTR-601-45, for boys and young men with Duchenne Muscular Dystrophy (DMD). It checks their long-term safety and how well they work to improve muscle health.
For: Duchenne Muscular Dystrophy (DMD)Belgium · Italy · Netherlands